A5016929439- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Genetic Associations and Epidemiology
- Peptidase Inhibition and Analysis
- Herpesvirus Infections and Treatments
- Gastric Cancer Management and Outcomes
- Mosquito-borne diseases and control
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Healthcare Policy and Management
- Sexual Differentiation and Disorders
- Prostate Cancer Treatment and Research
- Genomics and Rare Diseases
- Immune Response and Inflammation
- HER2/EGFR in Cancer Research
- Cytomegalovirus and herpesvirus research
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Hormonal and reproductive studies
- Blood disorders and treatments
- Machine Learning in Healthcare
Dana-Farber Cancer Institute
2005-2018
Brigham and Women's Hospital
2007-2014
Harvard University
2010-2014
RTI International
2011
Beth Israel Deaconess Medical Center
2007-2009
Dana-Farber Brigham Cancer Center
2009
Massachusetts General Hospital
2006
Loyola University Chicago
1996
The potential for genome-wide association studies to relate phenotypes specific genetic variation is greatly increased when data can be combined or compared across multiple studies. To facilitate replication and validation studies, RTI International (Research Triangle Park, North Carolina) the National Human Genome Research Institute (Bethesda, Maryland) are collaborating on consensus measures Phenotypes eXposures (PhenX) project. goal of PhenX identify 15 high-priority, well-established,...
Epidermal growth factor receptor ( EGFR ) tumour genotyping is crucial to guide treatment decisions regarding the use of tyrosine kinase inhibitors in nonsmall cell lung cancer (NSCLC). However, some patients may not be able obtain testing, either because tissue limited and/or tests are routinely offered. Here, we aimed build a model-based nomogram allow for prediction presence mutations NSCLC. We retrospectively collected clinical and pathological data on 3,006 with NSCLC who had their...
7148 Background: Chemotherapy for patients ≥ 70 with advanced NSCLC is associated survival benefits but increased toxicity compared younger patients. Erlotinib has shown promising activity and a tolerable side effect profile, it been approved in the treatment of who have failed prior chemotherapy. We conducted single center, phase II trial erlotinib years previously untreated NSCLC. Methods: Patients were chemotherapy-naïve, IIIB/IV, PS 0–2, enrolled treated erlotinib, 150 mg p.o.q.d, until...
8035 Background: There is increasing interest in the impact of EGFR and KRAS genotype on patterns response resistance NSCLC pts treated with gefitinib or erlotinib. We created a mutation registry to track protocol-based clinical outcomes specific mutations initially an EGFR-TKI. Methods: To date, 5 trials performed US Europe have been included this registry. These include: 1) erlotinib age > 70 yrs; 2) unselected pts; 3) known mutations; 4) bronchioloalveolar carcinoma (BAC) adenocarcinoma...
8065 Background: This single-arm phase II study explored the role of clinical characteristics (female gender, adenocarcinoma histology, no tobacco within 1 year) in selecting pts for 1st-line therapy w/ erlotinib. Available tissue EGFR mutation analysis was required to assess its impact on outcomes. Methods: Eligible were chemotherapy-naïve women, stage IIIB/ IV, PS 0–2, adenocarcinoma, and available status. Pts received erlotinib 150 mg PO daily until disease progression or unacceptable...
7591 Background: Erlotinib is associated with a survival benefit over placebo for pts advanced NSCLC who had received 1–2 prior regimens. Its role as initial therapy in clinically defined subgroups or prospectively tested EGFR mutations less clear. Methods: Chemotherapy-naive women adenocarcinoma, stage IIIB/IV, PS 0–1, formerly never smoked, were enrolled and treated erlotinib 150 mg PO daily, until the time of disease progression unacceptable toxicity. Response rate was primary endpoint....
7607 Background: The impact of tumor genotype and targeted therapies on the control development CNS metastases from NSCLC has not been extensively studied. We recently reported a lower than expected rate progression in patients with advanced somatic EGFR mutations initially treated gefitinib or erlotinib. This retrospective study was undertaken to investigate erlotinib versus chemotherapy risk mutant patients. Methods: Patients stage IV relapsed seen at DFCI between 8/00 2/10 who were...
7517 Background: Systematic genomic testing to identify potential predictive biomarkers select targeted therapy is emerging for NSCLC. DFCI introduced systematic mutations in BRAF, HER2, PIK3CA and EML4-ALK translocations addition routine characterization of EGFR KRAS July 2009 as part a prospective study. One half years have passed, thus we report our initial experience. Methods: Providers consented patients with advanced non-squamous Pathology specimens were dissected analyzed by...
7168 Background: Elderly patients derive survival benefit but significant toxicity from chemotherapy for NSCLC. Erlotinib is associated with reasonable and has a relapsed previously treated 1–2 regimens. This targeted agent may prove an effective well-tolerated first-line therapy in elderly advanced disease. Methods: 80 (chemo-naïve, age ≥ 70, PS 0–2, stage IIIB/IV NSCLC) were erlotinib 150 mg/d as part of phase II study. Primary endpoint was survival. QoL secondary endpoint, assessed by...
7016 Background: NSCLC pts with EGFR mutations have improved outcomes EGFR-targeted therapy and chemotherapy, compared to wild-type (wt) pts. There is in vitro clinical evidence suggest that may also confer radiation sensitivity. We examined locally advanced known mutation status assess for differences locoregional recurrence rates (LRR) after thoracic (TRT). Methods: retrospectively reviewed 1445 who underwent testing at our centers from 2004-09 identified 109 were treated TRT. LRR, distant...
TPS215 Background: Although EGFR tyrosine kinase inhibitors (TKIs) are very effective at treating EGFR-addicted cancers, resistance almost invariably occurs. It has been suggested that tumor cells may become resistant to TKIs by upregulating survival signaling via ErbB3 dependent activation of the PI3K/AKT pathway. In NSCLC tumors harbor wildtype EGFR, simultaneous inhibition and produces an additive effect on growth preclinically. MM-121 is a monoclonal antibody (MAb) pre-clinical activity...
8059 Background: Case reports have shown that EGFR-TKI’s can be effective against brain mets from NSCLC. It is unclear, however, what effect these agents might on the rate and time to occurrence of CNS or progression. Methods: We conducted a comprehensive review our institution’s patient database identify those pts who had been treated for NSCLC between 5/01 8/07. All provided informed consent included in database. To isolate role EGFR-TKI’s, received first-line EGFR-TKI were compared with...
7543 Background: Gefitinib and erlotinib can penetrate into the CNS elicit intracranial responses. However, there is incomplete data about their impact on development control of metastases. The experience at DFCI was reviewed to determine risk progression in patients with somatic EGFR mutations advanced NSCLC treated initially gefitinib or erlotinib. Methods: We identified stage IIIB IV as initial therapy for between 1/01 2/09. cumulative brain relapse calculated using death a competing...